RxDoctor Payments Data

Christopher Oglesby, DO

Gastroenterology · Monroe, LANPI 1184155129

Payments from drug & device makers

$6,440in general payments, 2019–2025

Across 324 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$886
  • Takeda Pharmaceuticals U.S.A., Inc.$539
  • Johnson & Johnson$450
  • Boston Scientific$446
  • Daiichi Sankyo Inc.$227
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,440100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,440 in reported general payments places this provider in the 65th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$93,992
Medicare patients
384
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin21$61,293
TrulancePlecanatide27$16,612
LinzessLinaclotide15$7,855
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl184$2,643
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates41$2,484
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl108$1,658
Omeprazole137$1,598
Esomeprazole Magnesium25$805
Dicyclomine Hcl21$482
Pantoprazole Sodium81$445
Doxycycline Monohydrate15$296
Metoclopramide Hcl26$233
Metronidazole17$125
Famotidine17$81
Carvedilol19$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$886$77,90548 claims
AbbVieLinzess$1,909$7,85515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →